Position paper of the Italian Society for the study of Dementias (Sindem) on the proposal of a new Lexicon on Alzheimer disease

Musicco, Massimo; Padovani, Alessandro; Sorbi, Sandro; Scarpini, Elio; Caffarra, Paolo; Cappa, Stefano F.; Clerici, Francesca; Tabaton, Massimo; Caltagirone, Carlo; Bonavita,; Bruni, Amalia C.; Bruno, Giuseppe; Federico, Antonio; Ferrarese, Carlo; Marra, Camillo; Nacmias, Benedetta; Parnetti, Lucilla; Pettenati, Carla; Sorrentino, Giuseppe; Tagliavini, Fabrizio; Mariani, Claudio

doi:10.1007/s10072-011-0825-8

Cited by 6 publications

(3 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The new criteria proposed a common lexicon for the clinical and research sectors [12], which has generated much debate in the scientific community [14][15][16]. Developments in the field of biomarkers and the use, alongside traditional genetics, of new more specific and more sensitive techniques were crucial for the development of these new criteria, but also for redefining frontotemporal dementia (FTD) and its subtypes.…”

Section: New Diagnostic Criteriamentioning

confidence: 99%

FDG PET and the genetics of dementia

Nacmias

Berti

Piaceri

et al. 2013

Clin Transl Imaging

Self Cite

View full text Add to dashboard Cite

Dementias are the most common neurodegenerative diseases and they are increasingly becoming a major public health problem. The most common form of dementia, affecting over 20 million people worldwide, is Alzheimer's disease (AD). AD is a neurodegenerative disease of the central nervous system mainly found in older adults, with an incidence that increases with age. With the development of newer technologies, including genetic screening technologies and PET/MRI scanning, the role of genetic studies and neuroimaging is being redefined; indeed, these approaches are able to provide support not only in the clinical diagnosis of dementia, but also in its presymptomatic evaluation. Many researchers agree that early identification of AD, before abnormal accumulation of amyloid and tau proteins, could provide an opportunity to hinder the progression of the disease. [18 F]2-fluoro-2-deoxy-D-glucose (FDG) PET studies have shown that decreased glucose metabolism in AD precedes clinical diagnosis and that the degree of clinical disability in AD correlates closely with the magnitude of the reduction in brain glucose metabolism. Data on presymptomatic mutation carriers from families with known early-onset autosomal dominant AD (familial AD) show reductions in the cerebral metabolic rate of glucose (CMRglc), consistent with the expected AD PET pattern, in the absence of severe atrophy on MRI. These results suggest that PET CMRglc measures have the potential to serve as preclinical biomarkers of dementia, useful also for tracking disease progression. This review highlights the role of genetics and FDG PET in understanding the pathogenesis of dementia.

show abstract

Section: New Diagnostic Criteriamentioning

confidence: 99%

FDG PET and the genetics of dementia

Nacmias

Berti

Piaceri

et al. 2013

Clin Transl Imaging

Self Cite

View full text Add to dashboard Cite

show abstract

“…Obviously, this proposal facilitated the AD trials and has been accepted by many investigators. Otherwise, numerous critiques have emerged regarding the new biological criteria for AD [268,269], some of them being severe because they affected the methodology and its ethical aspects [138,[269][270][271][272][273]. Therefore, in this very critical context of biological and clinical breakaway, the relevant modification of the new conceptualization of AD presented by Dubois et al, in 2021 [274], with the inclusion of clinical dementia in its definition is comprehensible.…”

Section: Evolution Of the Concept And Definition Of Admentioning

confidence: 99%

Controversial Past, Splendid Present, Unpredictable Future: A Brief Review of Alzheimer Disease History

Bermejo-Pareja,

del Ser

2024

JCM

View full text Add to dashboard Cite

Background: The concept of Alzheimer disease (AD)—since its histological discovery by Alzheimer to the present day—has undergone substantial modifications. Methods: We conducted a classical narrative review of this field with a bibliography selection (giving preference to Medline best match). Results: The following subjects are reviewed and discussed: Alzheimer’s discovery, Kraepelin’s creation of a new disease that was a rare condition until the 1970′s, the growing interest and investment in AD as a major killer in a society with a large elderly population in the second half of the 20th century, the consolidation of the AD clinicopathological model, and the modern AD nosology based on the dominant amyloid hypothesis among many others. In the 21st century, the development of AD biomarkers has supported a novel biological definition of AD, although the proposed therapies have failed to cure this disease. The incidence of dementia/AD has shown a decrease in affluent countries (possibly due to control of risk factors), and mixed dementia has been established as the most frequent etiology in the oldest old. Conclusions: The current concept of AD lacks unanimity. Many hypotheses attempt to explain its complex physiopathology entwined with aging, and the dominant amyloid cascade has yielded poor therapeutic results. The reduction in the incidence of dementia/AD appears promising but it should be confirmed in the future. A reevaluation of the AD concept is also necessary.

show abstract

“…The results were summarised in two series of recommendation papers, one from the International Working Group for New Research Criteria for the Diagnosis of AD (IWG), [2][3][4] the other, from the National Institute on Aging-Alzheimer's Association (NIA-AA). [5][6][7] Later, the Italian Society for the study of Dementias (SINDEM) 8 adhered to part of the IWG positions.…”

Section: Introductionmentioning

confidence: 99%

A Note on Changing Approach to Diagnosis of Alzheimer’s Disease

Tartaglione¹,

Sette²

2014

EMJ Neurol

View full text Add to dashboard Cite

This short review summarises the conclusions of two different series of studies set out to revise the 1984 National Institute of Neurological and Communicative Disorders and Stroke – Alzheimer’s disease and Related Disorders Association (NINCDS-ADRDA) criteria for the diagnosis of Alzheimer’s disease (AD). The role of AD-pathology (AD-P), the characteristics of AD clinical expression, and the importance of positivity of biomarkers are concisely surveyed, and the diverging position of different research groups in reference to predementia AD are outlined. The importance of other factors such as age, inflammatory changes, and vascular pathology, which can variably interact with the main feature of AD, is signalled and some clinical questions are raised.

show abstract

Position paper of the Italian Society for the study of Dementias (Sindem) on the proposal of a new Lexicon on Alzheimer disease

Cited by 6 publications

References 47 publications

FDG PET and the genetics of dementia

FDG PET and the genetics of dementia

Controversial Past, Splendid Present, Unpredictable Future: A Brief Review of Alzheimer Disease History

A Note on Changing Approach to Diagnosis of Alzheimer’s Disease

Contact Info

Product

Resources

About